Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2017-01-31
- Target Recruit Count
- 53
- Registration Number
- NCT01718327
- Locations
- 🇫🇷
Institut Mutualiste Montsouris, Paris, France
🇫🇷Hôpital Beaujon, Clichy, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
- Conditions
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- AB Science
- Target Recruit Count
- 258
- Registration Number
- NCT01694277
- Locations
- 🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷Hôpital l'Archet 2- Service de Cancérologie Digestive, Nice, France
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
- Conditions
- Interventions
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01673386
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
- First Posted Date
- 2012-08-14
- Last Posted Date
- 2022-06-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT01664182
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope South Pasadena, South Pasadena, California, United States
🇺🇸Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 43
- Registration Number
- NCT01636908
- Locations
- 🇳🇱
VUMedical Center, Amsterdam, Netherlands
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT01621568
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2012-06-15
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT01620216
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
- First Posted Date
- 2012-03-12
- Last Posted Date
- 2019-10-29
- Target Recruit Count
- 124
- Registration Number
- NCT01551459
- Locations
- 🇬🇧
Clatterbridge Centre for Oncology NHS Foundation Trust, Wirral, United Kingdom
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
- Conditions
- Interventions
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2012-03-08
- Target Recruit Count
- 12
- Registration Number
- NCT01548170
- Locations
- 🇪🇸
Hospital Universitario Ramón y Cajal, Madrid, Spain
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT01525550
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇷🇴Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania
🇮🇳Tata Memorial Hospital, Mumbai, Maharashtra, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.